6550--VISN 22 Methicillin-Resistant Staphylococcus Aureus Cost Per Test (CPT)
Closed Pre-Solicitation Posted
- Solicitation number
- 36C26226Q0064
- Agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- See Sow, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 (VISN 22) is seeking a cost-per-test solution for molecular diagnostic testing equipment and services, with a primary focus on Methicillin-Resistant Staphylococcus Aureus (MRSA) testing across eight VA facilities located in New Mexico, Arizona, and California. The procurement requires a PCR-based analyzer capable of performing multiple clinical diagnostic tests including MRSA surveillance, Clostridium difficile detection, CT/NG testing, tuberculosis testing, respiratory panels, and various other molecular diagnostics. Key contract requirements include random access capability, bi-directional bar-code interfacing, FDA approval, Windows operating software, 90% monthly equipment uptime, 24/7 technical support with emergency repair within 24 hours, comprehensive validation studies, and interface compatibility with VA laboratory systems. The Statement of Work emphasizes a comprehensive solution encompassing equipment installation, maintenance, reagents, supplies, and training, with the contractor maintaining ownership of equipment throughout the contract period. The Response to Information deadline is November 13, 2025, at 9:00 AM Pacific Time, with responses to be submitted to Carlos Magana at Carlos.Magana@va.gov.
This pre-solicitation notice contains no specific set-aside designations; however, the Request for Information document explicitly encourages participation from small businesses, including Service Disabled Veteran Owned Small Businesses (SDVOSB), Veteran Owned Small Businesses (VOSB), HUBZone, and Woman Owned Small Businesses (WOSB). No incumbent contractor or current contract holder is identified in the available documents. The pricing schedule indicates estimated annual test volumes of 364,758 tests across 19 different molecular diagnostic tests, with projected increases of 3% annually over a five-year base contract period plus four option years; however, all pricing columns are currently showing $0.00, indicating this is a preliminary draft solicitation. Qualified respondents must be authorized resellers, distributors, or dealers of original equipment manufacturers, with verification of OEM authorization required, and remanufactured or gray market items are explicitly prohibited. The 90-day implementation timeline begins upon contract award, with performance to occur across the eight specified VA medical facilities in the VISN 22 region.
Notice text
****See attachments for complete details****
Files
| File | Type | Posted |
|---|---|---|
| Statement of Work.docx | DOCX document | |
| Attachment A-Molecular Schedule of Pricing.xlsx | XLSX spreadsheet | |
| RFI Doc.docx | DOCX document | |
| 36C26226Q0064.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC | Veterans Integrated Service Network 20 | No set-aside | |
| 6550--VISN Cepheid GeneXpert Testing Supplies Base Plus 3 Op Yr RFQ | Veterans Integrated Service Network 5 | No set-aside | |
| 6550--Cepheid GeneXpert Testing Supplies | Veterans Integrated Service Network 5 | No set-aside | |
| Q301--Reference Laboratory Testing | Veterans Integrated Service Network 2 | No set-aside | |
| Emergent reference lab testing | Veterans Integrated Service Network 7 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity